127 related articles for article (PubMed ID: 29055795)
1. Small size mesoporous organosilica nanorods with different aspect ratios: Synthesis and cellular uptake.
Li Y; Guo W; Su X; Ou-Yang L; Dang M; Tao J; Lu G; Teng Z
J Colloid Interface Sci; 2018 Feb; 512():134-140. PubMed ID: 29055795
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin and doxorubicin high-loaded nanodrug based on biocompatible thioether- and ethane-bridged hollow mesoporous organosilica nanoparticles.
Zhang J; Weng L; Su X; Lu G; Liu W; Tang Y; Zhang Y; Wen J; Teng Z; Wang L
J Colloid Interface Sci; 2018 Mar; 513():214-221. PubMed ID: 29153715
[TBL] [Abstract][Full Text] [Related]
3. Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer.
Wang M; Liu W; Zhang Y; Dang M; Zhang Y; Tao J; Chen K; Peng X; Teng Z
J Colloid Interface Sci; 2019 Mar; 538():630-637. PubMed ID: 30554096
[TBL] [Abstract][Full Text] [Related]
4. A Facile Multi-interface Transformation Approach to Monodisperse Multiple-Shelled Periodic Mesoporous Organosilica Hollow Spheres.
Teng Z; Su X; Zheng Y; Zhang J; Liu Y; Wang S; Wu J; Chen G; Wang J; Zhao D; Lu G
J Am Chem Soc; 2015 Jun; 137(24):7935-44. PubMed ID: 26030506
[TBL] [Abstract][Full Text] [Related]
5. Biodegradable ethylene-bis(propyl)disulfide-based periodic mesoporous organosilica nanorods and nanospheres for efficient in-vitro drug delivery.
Croissant J; Cattoën X; Man MW; Gallud A; Raehm L; Trens P; Maynadier M; Durand JO
Adv Mater; 2014 Sep; 26(35):6174-80. PubMed ID: 25042639
[TBL] [Abstract][Full Text] [Related]
6. Soft mesoporous organosilica nanorods with gold plasmonic core for significantly enhanced cellular uptake.
Chen K; Tao J; Shi W; Su X; Cao X; Peng X; Bao L; Feng Z; Zhao Y; Mai X; Wang L; Lu G; Teng Z
J Colloid Interface Sci; 2019 Aug; 550():81-89. PubMed ID: 31055140
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of sandwich-like molybdenum sulfide/mesoporous organosilica nanosheets for photo-thermal conversion and stimuli-responsive drug release.
Su X; Wang J; Zhang J; Yuwen L; Zhang Q; Dang M; Tao J; Ma X; Wang S; Teng Z
J Colloid Interface Sci; 2017 Jun; 496():261-266. PubMed ID: 28235720
[TBL] [Abstract][Full Text] [Related]
8. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
9. Dendrimer-like mesoporous silica nanospheres with suitable surface functionality to combat the multidrug resistance.
Xu W; Gao X; Ge P; Jiang F; Zhang X; Xie J
Int J Pharm; 2018 Dec; 553(1-2):349-362. PubMed ID: 30393166
[TBL] [Abstract][Full Text] [Related]
10. A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells.
Song Q; Chuan X; Chen B; He B; Zhang H; Dai W; Wang X; Zhang Q
Drug Deliv; 2016 Jun; 23(5):1734-46. PubMed ID: 25853477
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable Mesoporous Organosilica Nanosheets for Chemotherapy/Mild Thermotherapy of Cancer: Fast Internalization, High Cellular Uptake, and High Drug Loading.
Chen L; Meng X; Liu M; Lv R; Cai B; Wang Z
ACS Appl Mater Interfaces; 2020 Jul; 12(27):30234-30246. PubMed ID: 32525649
[TBL] [Abstract][Full Text] [Related]
12. Virus-mimicking mesoporous organosilica nanocapsules with soft framework and rough surface for enhanced cellular uptake and tumor penetration.
Tao J; Chen K; Su X; Ren L; Zhang J; Bao L; Dong H; Lu G; Teng Z; Wang L
Biomater Sci; 2020 Apr; 8(8):2227-2233. PubMed ID: 32129325
[TBL] [Abstract][Full Text] [Related]
13. Facile Synthesis of Yolk-Shell-Structured Triple-Hybridized Periodic Mesoporous Organosilica Nanoparticles for Biomedicine.
Teng Z; Zhang J; Li W; Zheng Y; Su X; Tang Y; Dang M; Tian Y; Yuwen L; Weng L; Lu G; Wang L
Small; 2016 Jul; 12(26):3550-8. PubMed ID: 27183872
[TBL] [Abstract][Full Text] [Related]
14. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
15. Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles.
Gao Y; Chen Y; Ji X; He X; Yin Q; Zhang Z; Shi J; Li Y
ACS Nano; 2011 Dec; 5(12):9788-98. PubMed ID: 22070571
[TBL] [Abstract][Full Text] [Related]
16. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
[TBL] [Abstract][Full Text] [Related]
17. Fabrication of biodegradable auto-fluorescent organosilica nanoparticles with dendritic mesoporous structures for pH/redox-responsive drug release.
Li X; Chen Y; Zhang X; Zhao Y
Mater Sci Eng C Mater Biol Appl; 2020 Jul; 112():110914. PubMed ID: 32409066
[TBL] [Abstract][Full Text] [Related]
18. Biodegradable Periodic Mesoporous Organosilica (BPMO) Loaded with Daunorubicin: A Promising Nanoparticle-Based Anticancer Drug.
Mai NXD; Birault A; Matsumoto K; Ta HKT; Intasa-Ard SG; Morrison K; Thang PB; Doan TLH; Tamanoi F
ChemMedChem; 2020 Apr; 15(7):593-599. PubMed ID: 32020745
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
20. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
